PODD INSULET CORP Insider Trading

Director Timothy C. Stonesifer buys 2,790 shares of INSULET CORP (PODD) at $143.51; stock down 59.6% from 52-week high.

Timothy C. Stonesifer purchased 2,790 shares at $143.51, increasing his holdings by 44.6% to 9,041 shares post-transaction. The stock is currently trading at $143.30, down 59.6% from its 52-week high of $354.88 and down 40.5% over the past 90 days. His prior open-market purchase at PODD on 2025-12-05 showed a 90-day return of -22.7%, and across his cross-ticker track record, his 1 prior buy averaged -22.7% over 90 days with a 0.00% win rate. The company's fundamentals show $761.7M in latest quarterly revenue with +30.7% annual growth and net income of $91.1M, though the P/E of 32.79 and market cap of $9.9B place it in a higher valuation context. The timing of this purchase against the stock's recent sharp decline and the director's historical pattern of unfavorable post-purchase returns warrants examination.

Director Elizabeth H Weatherman buys 3,450 shares of PODD at $144.20; stock down -59.6% from 52-week high.

Elizabeth H Weatherman, a director at Insulet, purchased 3,450 shares at $144.20 on June 3, 2026, increasing her holdings by 50.0% to 10,352 shares. The purchase occurs against a backdrop of significant stock weakness: the shares have declined 59.6% from the 52-week high of $354.88 and fallen 40.5% over the past 90 days. The company's fundamentals remain solid with $761.7M in latest quarterly revenue, 30.7% annual growth, and $91.1M in net income, suggesting the stock decline reflects valuation compression or market sentiment rather than operational deterioration. The size and nature of this director-level acquisition of 3.4K shares in a large-cap company (market cap $9.9B) reflects a material personal investment decision, though without context on the director's compensation structure, vesting schedules, or prior trading patterns at this ticker, the specific motivation remains observational.

PODD Director Minogue buys 2,030 shares at $246.23; stock down 28.7% from 52-week high.

Director Michael R. Minogue purchased 2,030 shares at $246.23, increasing his holding to 17,483 shares (+13.1% vs pre-transaction holdings). The timing presents a mixed picture: while the purchase occurred at a price 5.1% below the 30-day average, the stock has declined 28.7% from its 52-week high of $352.82, and Minogue's own prior trade at PODD (a buy on 2023-05-23) returned -35.5% over 90 days, suggesting a historical pattern of unfavorable timing at this ticker. Insulet's fundamentals remain strong with annual revenue growth of +30.7% and quarterly revenue of $706.3M, but the company trades at a steep P/E of 235.05, and the stock's recent 90-day decline of 23.1% contrasts with the insider's decision to add shares. The purchase warrants observation as it occurs during a period of significant valuation and price pressure rather than during demonstrably favorable entry points.

CEO McEvoy buys 4,300 PODD shares for $1.0M, raising stake 44.7% to 13.9K shares amid 29.3% pullback from high

McEvoy Ashley, President and CEO, purchased 4,300 shares at $239.35 on 2026-02-20 for $1,029,205.00, increasing holdings by 44.7% from 9,616 to 13,916 shares. The transaction occurred as the stock trades at $249.38, down 29.3% from its 52-week high of $352.82 and down 24.2% over the past 90 days. Against a backdrop of strong fundamentals—annual revenue growth of 30.7% and a market cap of $17.6B—this open-market buy by the top executive represents a material increase in personal exposure at a marked discount to recent peaks. The elevated P/E of 233.07 relative to near-term price momentum suggests the executive's conviction at current levels warrants investor attention.

Director Timothy Stonesifer buys 962 PODD shares at $311.73; holdings surge 26.5% to 4,591 shares

Timothy C. Stonesifer, a director, purchased 962 shares at $311.73, raising his stake by 26.5% from 3,629 to 4,591 shares and investing $299,884.26 in the transaction. The purchase occurred at a price $15.54 above the current market price of $296.19, and notably occurred near the stock's recent 52-week peak (down only 16.0% from the high of $352.82), suggesting the director deployed capital when the stock was not depressed. Insulet operates on a strong financial foundation with $706.3M in latest-quarter revenue, annual growth of 22.1%, and $87.6M in net income, though the valuation reflects a high P/E of 84.63. The transaction represents a discrete director accumulation event, but without historical track record data or disclosure of prior patterns at this ticker, the directional conviction indicated by this 26.5% holdings increase warrants monitoring for potential alignment signals.

EVP Benjamin Eric sold 4,263 shares of PODD at $332.23 on 2025-08-21 under 10b5-1 plan; post-sale holdings: 16,736 shares

Benjamin Eric, EVP of CPXO, sold 4,263 shares of Insulet Corp (PODD) for a total value of $1,416,296.49 as part of a pre-arranged 10b5-1 trading plan, reducing his holdings by 20.3% to 16,736 shares. Since this transaction was scheduled under a Rule 10b5-1 plan rather than discretionary, it reflects a predetermined execution rather than a timing decision by the executive. The sale represents a significant proportional reduction in his position but does not provide evidence of a sudden change in conviction given the systematic nature of the plan.

SVP General Counsel Kapples sells 5,278 PODD shares at $318.47; holds 23,180 post-transaction, stock now at 52-week high of $322.02

Kapples sold 5,278 shares representing an 18.5% reduction in his 28,458-share position at $318.47, with the stock currently trading at $322.02—near its 52-week high of $322.02. The sale occurred as INSULET has delivered strong fundamentals: annual revenue growth of +22.1%, quarterly revenue of $569.0M, and net income of $35.4M, though the company trades at a P/E of 56.30. The transaction's timing at near-peak valuation levels and the 30-day price appreciation of +25.6% provides context for understanding the sale in relation to recent market momentum. With 23,180 shares retained post-sale, Kapples maintains a material stake in the company.

Director Hopfield Jessica sells 5,235 shares of PODD at $317.54 for $1.7M; stock now at 52-week high.

Director Hopfield Jessica sold 5,235 shares at $317.54 on 2025-05-13, reducing her holdings from 32,152 to 26,917 shares. The sale occurred as PODD stock reached its 52-week high of $321.41, with the stock up +25.8% over the prior 30 days and +13.9% over 90 days. In her prior sales at PODD, the stock subsequently rose +22.0% over 90 days—a pattern consistent with selling before periods of continued appreciation. INSULET's fundamentals show strong revenue growth of +22.1% year-over-year with a P/E of 56.19, indicating the market has priced in significant future performance expectations. The sale's magnitude (16.3% of her pre-transaction holdings) is moderate and occurred near peak valuation, though the director retains substantial equity exposure with 26,917 shares remaining.

EVP Benjamin Eric sold 12,394 shares of PODD at $280.00 (-52.1% of holdings) for $3,470,320.00

Benjamin Eric, EVP at INSULET CORP (PODD), sold 12,394 shares at $280.00 on 2025-01-21, reducing his holdings from 23,777 shares to 11,383 shares (a -52.1% reduction). The sale occurred at the company's 52-week high of $278.89, coinciding with strong recent momentum: the stock is up 5.9% over 30 days and 17.4% over 90 days. The company shows solid fundamentals with annual revenue growth of +30.0% and a P/E of 46.48, though the valuation reflects elevated expectations typical of growth-oriented medical device manufacturers. His prior sell at this ticker on 2024-12-16 generated a -1.2% return over 30 days, providing limited historical context for this ticker's sell-timing patterns.

EVP Benjamin Eric sold 4,362 shares of PODD at $267.60 for $1.2M, reducing holdings by 18.9% to 18,702 shares

Benjamin Eric sold 4,362 shares (4.4K shares) at $267.60, representing a substantial 18.9% reduction in his PODD holdings from 23,064 shares to 18,702 shares. The sale occurred near the 52-week high of $275.70, with the stock currently at $263.35. INSULET is trading at a P/E of 43.89 with strong fundamentals: $543.9M in latest quarterly revenue and $77.5M net income, supported by 30.0% annual revenue growth. The magnitude of the reduction and the proximity to recent highs merit investor attention in the context of the company's elevated valuation multiple.